Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venke Skibeli

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|June 28, 2005
A proteoglycan undergoes different modifications en route to the apical and basolateral surfaces of Madin-Darby canine kidney cellsHeidi Tveit, Gunnar Dick, Venke Skibeli, et al.
Medicine and Science in Sports and Exercise|April 6, 2004
Serum sTfR levels may indicate charge profiling of urinary r-hEPO in doping controlGro Nissen-Lie, Kåre Birkeland, Peter Hemmersbach, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 1, 2010
[Tigecycline--a new antibiotic]Venke Skibeli, Ingvild Aaløkken, Egil Lingaas, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
The Oncologist|January 25, 2015
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human useKyriaki Tzogani, Venke Skibeli, Ingunn Westgaard, et al.
Bioanalysis|January 19, 2018
Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdlesJoanne Goodman, Simon Cowen, Viswanath Devanarayan, et al.
The Oncologist|February 12, 2020
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell LymphomaSahra Ali, Rune Kjeken, Christiane Niederlaender, et al.
Bioanalysis|December 14, 2019
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (<u>Part 2</u> - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity)Brian Booth, Lauren Stevenson, Renuka Pillutla, et al.
Bioanalysis|December 11, 2019
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)Steven Piccoli, Devangi Mehta, Alessandra Vitaliti, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|June 28, 2005
A proteoglycan undergoes different modifications en route to the apical and basolateral surfaces of Madin-Darby canine kidney cellsHeidi Tveit, Gunnar Dick, Venke Skibeli, et al.
Medicine and Science in Sports and Exercise|April 6, 2004
Serum sTfR levels may indicate charge profiling of urinary r-hEPO in doping controlGro Nissen-Lie, Kåre Birkeland, Peter Hemmersbach, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 1, 2010
[Tigecycline--a new antibiotic]Venke Skibeli, Ingvild Aaløkken, Egil Lingaas, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
The Oncologist|January 25, 2015
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human useKyriaki Tzogani, Venke Skibeli, Ingunn Westgaard, et al.
Bioanalysis|January 19, 2018
Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdlesJoanne Goodman, Simon Cowen, Viswanath Devanarayan, et al.
The Oncologist|February 12, 2020
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell LymphomaSahra Ali, Rune Kjeken, Christiane Niederlaender, et al.
Bioanalysis|December 14, 2019
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (<u>Part 2</u> - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity)Brian Booth, Lauren Stevenson, Renuka Pillutla, et al.
Bioanalysis|December 11, 2019
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)Steven Piccoli, Devangi Mehta, Alessandra Vitaliti, et al.
Pageof 1